These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 36226464

  • 1. Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
    Dodick DW, Blumenfeld AM, Halker Singh RB, Williams R, Zhang F, Chen PW, Hsu CP, Peng C, Snellman J, Chehrenama M, Ailani J.
    Headache; 2023 Feb; 63(2):233-242. PubMed ID: 36226464
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J.
    Lancet; 2018 Nov 24; 392(10161):2280-2287. PubMed ID: 30360965
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.
    Ailani J, Kuruppu DK, Rettiganti M, Oakes T, Schroeder K, Wietecha L, Port M, Blumenfeld AM.
    Headache; 2022 Feb 24; 62(2):198-207. PubMed ID: 35076090
    [Abstract] [Full Text] [Related]

  • 7. No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study.
    Florescu AM, Lannov LV, Younis S, Cullum CK, Chaudhry BA, Do TP, Amin FM.
    Cephalalgia; 2024 Jan 24; 44(1):3331024231222915. PubMed ID: 38215232
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
    Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F, Picard H, Lenz R, Mikol DD.
    Cephalalgia; 2019 Jun 24; 39(7):817-826. PubMed ID: 30982348
    [Abstract] [Full Text] [Related]

  • 9. Timing and durability of response to erenumab in patients with episodic migraine.
    McAllister PJ, Turner I, Reuter U, Wang A, Scanlon J, Klatt J, Chou DE, Paiva da Silva Lima G.
    Headache; 2021 Nov 24; 61(10):1553-1561. PubMed ID: 34841526
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
    Tepper SJ, Ashina M, Reuter U, Hallström Y, Broessner G, Bonner JH, Picard H, Cheng S, Chou DE, Zhang F, Klatt J, Mikol DD.
    J Headache Pain; 2021 Jul 23; 22(1):81. PubMed ID: 34301173
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
    Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, Peng C, Xue F, Mikol DD.
    Headache; 2021 Apr 23; 61(4):653-661. PubMed ID: 33764538
    [Abstract] [Full Text] [Related]

  • 17. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
    Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Wright IK, Chou DE, Klatt J, Picard H, Lenz RA, Mikol DD.
    Neurology; 2020 Aug 04; 95(5):e469-e479. PubMed ID: 32636324
    [Abstract] [Full Text] [Related]

  • 18. Timing and durability of response to erenumab in patients with chronic migraine.
    Tepper SJ, Lucas S, Ashina M, Schwedt TJ, Ailani J, Scanlon J, Klatt J, Chou DE, Wang A, Paiva da Silva Lima G.
    Headache; 2021 Sep 04; 61(8):1255-1263. PubMed ID: 34363708
    [Abstract] [Full Text] [Related]

  • 19. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
    Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD.
    Neurology; 2019 May 14; 92(20):e2309-e2320. PubMed ID: 30996056
    [Abstract] [Full Text] [Related]

  • 20. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
    Diener HC, Ashina M, Ritter S, Paiva Da Silva Lima G, Rasmussen S, Zielman R, Tfelt-Hansen P.
    Cephalalgia; 2021 Oct 14; 41(11-12):1262-1267. PubMed ID: 33939497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.